This author has not written his bio yet.
But we are proud to say that wp_art_ad-biotech contributed 23 entries already.
Under the title:” development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications”, in short “Plurivax”, the EU cooperation is part of the recent 8th EuroTransBio call and will be funded for a three year period supported by the German Federal Ministry of Education and Research (BMBF) and […]
ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI). The project will use exciting novel technology developed at the Burnet Institute. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the […]
ARTES Biotechnology has entered into a strategic collaboration with a subsidiary of Sun Pharmaceutical Industries Ltd, an international specialty pharmaceutical company with a diversified product portfolio headquartered in Mumbai/India. This step broadens ARTES’ international client base and demonstrates its ability to attract blue chip pharmaceutical companies. Under the collaboration agreement, ARTES will be responsible to […]
Meet us at the 2nd Annual Phacilitate Partnering for Vaccine Emerging Markets event in Amsterdam, May 28th ‑29th or contact us previously for a personal meeting! We look forward to meeting you! http://www.phacilitate.co.uk/vaccine-emerging-markets/
ARTES Biotechnology GmbH is part of the international consortium While the oil is slowly but surely running out, renewable resources are becoming increasingly important. In future, the biological production of raw materials has to play an even greater role to meet the needs in an environmentally friendly manner. An international consortium of researchers and companies […]
A leading consortium of industrial partners has been awarded a grant by the Seventh Framework Program of the European Union for an innovative research and development project “TA101 GOCLIN: Clinical development of TA-101 for the treatment of rheumatoid arthritis“ (#606352). The aim of this Project is to take TA101, a small domain antibody developed by […]
ARTES and Bio Farma announced today to join forces for the development and manufacturing of vaccine candidates. The agreed collaboration involved the strength of both partners. ARTES is specialized in cell line and process development, VLP based vaccines as well as in technology transfer for pharmaceutically relevant production processes whereas Bio Farma is involved in […]
ARTES announced the collaboration with Midas for strategic marketing opportunities. Aim of the cooperation is the finding of suitable partners for defined pharmaceuticals projects like vaccine and pharmaceutical target development or transfer of Biosimilar processes. ARTES is specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry whereas […]
ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent for their VLP platform. The patent will further strengthen the Metavax® platform of the company. In combination with the expression platform Hansenula Metavax® is a unique […]
ARTES has launched a new website, incorporating new content to give a better view on the current business and added offer. The new site especially features an overview of ARTES’ business expansion in technology transfer and its Metavax® approach for VLP-based vaccine development.